Lee, Chia-Chia
Chang, Ching-Pang
Lin, Chun-Jung
Lai, Hsing-Lin
Kao, Yu-Han
Cheng, Sin-Jhong
Chen, Hui-Mei
Liao, Yu-Ping
Faivre, Emilie
Buée, Luc
Blum, David
Fang, Jim-Min
Chern, Yijuang http://orcid.org/0000-0002-5842-5429
Funding for this research was provided by:
Academia Sinica and Ministry of Science and Technology (MOST 104-0210-01-09-02, MOST 105-0210-01-13-01, MOST 106-0210-01-15-02)
Inserm, Université Lille, France Alzheimer, programs d’investissements d’avenir LabEx
DISTALZ
ADORATAU and SPREADTAU
Fondation pour la Recherche Médicale
Vaincre Alzheimer
Fondation Plan Alzheimer
Lille Métropole Communauté Urbaine, Région Hauts-de-France
DN2M
Article History
Received: 10 January 2018
Accepted: 20 March 2018
First Online: 4 April 2018
Compliance with Ethical Standards
:
: Yijuang Chern and Jim-Min Fang hold patents in adenosine compounds for the treatment of neurodegenerative diseases.